Public Health Agency of Canada
Symbol of the Government of Canada

Share this page

Blood Safety Contribution Program

The Blood Safety Contribution Program supports surveillance activities for blood, tissue, and organ related adverse events in an effort to maintain the safety of our health system:

The Agency is committed to updating preliminary summary data under these surveillance systems every six months.

Transfusion Error Surveillance System (TESS)

The Transfusion Error Surveillance System (TESS) was initiated in 2005 by the Public Health Agency of Canada (the Agency) to monitor errors occurring at any point in the transfusion chain. To date, 15 hospitals participate in the surveillance and report all transfusion-related errors to the Agency on a quarterly basis. By tracking transfusion-related errors it is possible to identify not only the points in the transfusion chain where errors most commonly occur, but also the points where changes can be implemented in order to limit the opportunity for transfusion errors.

Transfusion Transmitted Injuries Surveillance System (TTISS)

The Transfusion Transmitted Injuries Surveillance System (TTISS) is a voluntary nationwide ongoing surveillance system established by the Public Health Agency of Canada in 2001 to monitor serious, moderate, and selected minor transfusion-related adverse events occurring in Canadian healthcare settings. The TTISS collects data on adverse reactions related to the transfusion of blood components (red blood cells, granulocytes, platelets, plasma and cryoprecipitates) and blood products (plasma derivatives). Events are reported from an extensive network of hospitals throughout the country, covering all provinces and two territories.

Cells, Tissues and Organs Surveillance System (CTOSS)

The Cells Tissue and Organ Surveillance System (CTOSS) is a Public Health Agency of Canada surveillance initiative which began in 2007 as a pilot project to capture transplantation adverse events. The surveillance system is comprised of three components: cells, tissue and organ. The tissue component is well established with 5 pilot sites participating (Alberta, Ontario, Quebec, New Brunswick and Nova Scotia). CTOSS is now working to develop the organ component and the cell component will follow after that.

Additional Links